Multiple Myeloma is relatively a rare disease. It accounts for approximately 1% of all cancers and 10% of all blood and bone marrow cancers. For more information on Multiple Myeloma, click here-https://bit.ly/2HKs5da
Jan 5, 2021• Pharma, Latest Pharma News, Health News
Pfizer and OPKO Health: A step closer to FDA Nod for pediatric growth hormone deficiency (GHD) drug, Somatrogon Pfizer and Opko had joined...
Sep 7, 2020• Articles
The Multiple Myeloma Market is expected to grow during the study period 2017-30 due to a rich and robust pipeline, increasing incidence,...
Jun 4, 2019• Business Consultant, DelveInsight's Drug Report, DelveInsight's Oncology based Reports, Notizia - Recent Pharma, Healthcare and Biotech Happenings, Pharma Consultant
Sanofi’s Isatuximab combo extends lives in multiple myeloma Phase III trials of Sanofi’s investigational anti-CD38 monoclonal antibody,...
Mar 15, 2019• Articles
Multiple Myeloma, the second most common type of malignant cancer first being Non-Hodgkin lymphoma, is a type of cancer which is formed due...
Your email address will not be published. Required fields are marked *
Snippets - A Small piece of News or Article
Pharma, Latest Pharma News, Health News
Articles, Pharma news